SAN FRANCISCO, CA / ACCESSWIRE / January 9, 2020 / LACHESIS BIOSCIENCES LTD, a clinical-stage biotechnology company targeting dementia caused by Alzheimer's and Parkinson's disease, announced today that its chief executive officer, Dr. Tim Morgan, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.
To view the full release with downloadable images click here Click here
Key Takeaways
- Targeting Alzheimer's Disease with a Proven Mechanism of Action.
- 2 assigned patents for LBIO-R32 Offering Improved Tolerability vs. Existing Formulation of Rivastigmine.
- Expedited Path to Market with a significantly De-risked Asset.
.png)
About LACHESIS BIOSCIENCES
A clinical-stage biotechnology company using its patented, nasal drug delivery technology to advance treatments for dementia and agitation associated with Alzheimer's and Parkinson's disease.
Contact:
Tim Morgan
[email protected]
+61 418 138 877
Chief Executive Officer
SOURCE: Lachesis Biosciences Ltd.